Table 1.
Recent clinical trials on chemotherapy in patients with Rhabdomyosarcoma (RMS).
| Years | Phase | Chemotherapy Regimen | N | Patients | Clinical Significance | Ref. |
|---|---|---|---|---|---|---|
| 2019 | III | IVA with or without maintenance chemotherapy (VC) | 371 | Non-metastatic RMS | Five-year DFS: 77.6% with IVA/VC and 69.8% with IVA (p = 0.06) |
[27] |
| Five-year OS: 86.5% with IVA/VC and 73.7% with IVA (p = 0.01) | ||||||
| 2018 | III | IVA with or without Dox | 484 | Non-metastatic RMS | Three-year EFS: 67.5% with IVA/Dox and 63.3% with IVA (p = 0.33) |
[25] |
| 2018 | III | VAC or VAC/VI (substitution for half of VAC course by VI) | 448 | Intermediate-risk RMS | Four-year EFS: 63% with VAC and 59% with VAC/VI (p = 0.51) |
[28] |
| Four-year OS: 73% with VAC and 72% with VAC/VI (p = 0.80) less hematologic toxicities with VAC/VI | ||||||
| 2012 | II | Trabectedin | 50 | Recurrent sarcoma: RMS (23), EWS (16), and other sarcomas (11) | PR 2.5%, SD 7.5%, and PD 90% | [30] |
IVA: ifosfamide, vincristine, and dactinomycin; VC: vinorelbine and cyclophosphamide; VAC: vincristine, dactinomycin, and cyclophosphamide; VI: vincristine and irinotecan; RMS, rhabdomyosarcoma; EWS, Ewing sarcoma; DFS: disease-free survival; OS: overall survival; EFS: event-free survival; Dox: doxorubicin; PR, partial response; SD, stable disease; PD, progressive disease.